Cerecor picks up a Lilly antidepressant with ambitions in addiction

Cerecor acquired the rights to an Eli Lilly ($LLY) antidepressant, planning to take the drug into Phase II as a treatment for addictive disorders. The treatment, formerly LY2456302, bolsters the brain's kappa opioid receptors, an action Cerecor says has been tied to modulating stress and, importantly, blocking the physical and emotional symptoms of nicotine withdrawal. Under Lilly's watch, the drug proved safe and able to penetrate the blood-brain barrier in Phase I, and Cerecor plans to start a mid-stage trial of its own in the second half of 2015, rechristening the treatment CERC-501 and testing it in nicotine dependence. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.